Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity - 2Is Chinese food truly flavorful?
- 3Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- 4Famous SUVs With Low Energy Utilization In 2024
- 5Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza
- Wegmans recalls mixed nuts over salmonella contamination fears
- 7 Logically Demonstrated Techniques for Better Rest
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- Vote in favor of your Number one method for commending a birthday
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- Manual for 6 Hot Brilliant Beds
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- IDF drops over 80 explosives on Tehran weapon production sites in latest strike
- My Excursion to Monetary Autonomy: Awesome ways to save cash
